Browse the evidence

Female sex independently predicted greater TBWL, while insulin use and higher T2D medication burden were associated with less TBWL.

Understanding these predictors can help tailor treatment strategies for weight loss.

Both medications exhibited favorable cardiovascular profiles, though gastrointestinal adverse events constitute the predominant tolerability concern.

While both tirzepatide and retatrutide may improve cardiovascular health, practitioners should monitor for gastrointestinal side effects.

Bariatric surgery achieves 25%–35% total body weight loss with durability extending beyond 10 years.

Bariatric surgery should be considered for long-term weight management in obese patients.

Adjuvant GLP-1RA users achieved a higher mean proportion of days covered (PDC) of 74.30% compared to 66.91% for SGA-only users.

Incorporating GLP-1RA may enhance medication adherence in patients prescribed SGAs.

Adjuvant GLP-1RA users demonstrated longer persistence of 165.6 days compared to 139.2 days for SGA-only users.

GLP-1RA may help patients stay on their SGA medications longer.

Medicaid patients using adjuvant GLP-1RA showed a PDC of 88.25% compared to 70.32% for SGA-only users.

GLP-1RA may significantly improve adherence among Medicaid patients on SGAs.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 2.26 points in the SF-36 physical function domain.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

Tirzepatide increases HOMA-β and decreases HOMA-IR in T2D patients.

Tirzepatide may be effective in improving insulin sensitivity and β-cell function in T2D management.

Once-monthly maridebart is associated with HbA1c reductions of approximately 1.2–1.6 percentage points.

Clinicians can anticipate improvements in glycemic control with maridebart therapy.

Incretin-based therapies are effective but present limitations for long-term obesity management.

Practitioners should be aware of the limitations of incretin therapies in long-term obesity management.

Tirzepatide led to a greater reduction in median triglyceride levels compared with semaglutide.

Tirzepatide may be preferred for patients needing significant triglyceride reduction.

Short-term changes in glycaemic parameters were statistically associated with concurrent changes in fat-free mass, muscle strength, and resting metabolic rate.

Monitoring glycaemic parameters may provide insights into metabolic health during weight loss.

Early discontinuation of GLP-1RA therapy is associated with increased risks of coronary artery disease and heart failure.

Clinicians should be aware of the cardiovascular risks when patients discontinue GLP-1RA therapy early.

The addition of testosterone undecanoate improved insulin sensitivity and sexual health compared to tirzepatide monotherapy.

Clinicians should consider the potential benefits of testosterone therapy on metabolic and sexual health in this patient group.

Exercise counseling was documented more frequently among patients with durable weight loss after the last GLP-1RA prescription than among those with weight regain (26.2% vs. 14.7%; P = .04).

Incorporating exercise counseling may enhance weight maintenance outcomes for patients after GLP-1RA therapy.

GLP-1-Rezeptoragonisten, insbesondere Semaglutid, können kardiovaskuläre Ereignisse verhindern.

Semaglutid kann zur Prävention von Herz-Kreislauf-Erkrankungen bei übergewichtigen Patienten eingesetzt werden.

GLP-1 receptor agonist medications have the potential to promote marked weight loss.

Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.

Obesity should be framed as a chronic, multifactorial disease requiring comprehensive management strategies.

A multidisciplinary approach is essential for effective obesity management.

Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.

Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.

Current data indicate a rapid shift from single-pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes.

Practitioners should consider multimodal approaches as the future direction for treating obesity and type 2 diabetes.

The DRL agent achieved a prediction accuracy of optimal doses of 92%, exceeding traditional models by 15%.

The DRL agent can provide more accurate dosing recommendations compared to traditional methods.

In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia.

Retatrutide may improve glycemic control in patients with type 2 diabetes.

The guidelines focus on cardiovascular risk stratification and management of cardiovascular risk factors in diabetes.

Focus on cardiovascular risk factors is essential for diabetes management.

Quality of life, as measured by the Short Form-36 (SF-36), improved in the experimental group.

Improving quality of life is an important benefit of structured exercise for diabetic patients.